SCHEMBL2450640

SCHEMBL2450640

CC(C)(C)N(C(=O)O)c1cc(Oc2ccc([N+](=O)[O-])cn2)ccc1F

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 2/20 0.53
MAPT P10636 11/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RAB9A P51151 1/20 0.48
PPARG P37231 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
GAA P10253 2/20 0.43
LMNA P02545 5/20 0.41
HTT P42858 5/20 0.41
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
CYP2C19 P33261 1/20 0.40
HPGD P15428 2/20 0.39
KDM4E B2RXH2 2/20 0.38
PABPC1 P11940 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2450636 1.00 HSPB1 (0.53) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3510639 0.86 HSPB1 (0.55) HSPB1MAPTNPSR1RAB9AL3MBTL1
SCHEMBL3510643 0.86 HSPB1 (0.55) HSPB1MAPTNPSR1RAB9AL3MBTL1
SCHEMBL3511018 0.83 HSPB1 (0.49) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3511013 0.83 HSPB1 (0.49) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL2453206 0.83 KDM4E (0.47) RAB9ALMNAALDH1A1MEN1KMT2A
SCHEMBL3134680 0.83 HSPB1 (0.56) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3134665 0.83 HSPB1 (0.56) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3510832 0.82 HSPB1 (0.52) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3510827 0.82 HSPB1 (0.52) HSPB1MAPTNPSR1RAB9APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8697874-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-15 US disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-29 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 HSPB1 3348/4885MAPT 4439/4885NPSR1 3385/4885
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NR3C2, RAF1 HSPB1 2059/4885MAPT 4487/4885NPSR1 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.